Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

9-ING-41 in Pediatric Patients With Refractory Malignancies.

← catalyst calendar

NCT04239092

Sponsored by Actuate Therapeutics Inc. (industry) · ACTU — their whole pipeline →.

Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
40actual
Sites
9
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2020-06-05actualWhen the study began enrolling
Primary completion2025-07-07actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-07-07actualThe whole study's end, after follow-up
First posted2020-01-23actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-07-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Refractory Cancer
  • Refractory Neoplasm
  • Cancer Pediatric
  • Refractory Tumor
  • Pediatric Cancer
  • Pediatric Brain Tumor
  • Neuroblastoma
  • Neuroblastoma Recurrent
  • Pediatric Lymphoma
  • Pediatric Meningioma
  • Diffuse Intrinsic Pontine Glioma

Interventions

  • Drug: 9-ING-41 — also filed as 9-ING-41 COMPOUND
  • Drug: Irinotecan — also filed as CPT-11
  • Drug: Temozolomide — also filed as Temodar
  • Drug: Cyclophosphamide — also filed as Cyclophosphamide IV
  • Drug: Topotecan — also filed as Topotecan IV

Primary outcome

what the primary-completion date above is the date OF
Number of participants with treatment-related adverse events as assessed by CTCAE v5
measured 3-12 months

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ACTU's whole pipeline · Catalyst calendar · Every registered study · What changed